EMH.V - Emerald Health Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1650
+0.0050 (+3.13%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1600
Open0.1600
Bid0.1600 x 0
Ask0.1650 x 0
Day's Range0.1500 - 0.1650
52 Week Range0.1200 - 4.4600
Volume1,177,740
Avg. Volume686,851
Market Cap30.091M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.2240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.40
  • GlobeNewswire

    Emerald Health Therapeutics Proposes to Amend Warrant Terms

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that it intends to amend the terms of certain common share purchase warrants originally issued on September 9, 2019 (the “Warrants”). An aggregate of 12,500,000 Warrants were initially issued at an exercise price of $2.00 per common share of Emerald (each, a "Common Share") in connection with a $25,000,000 convertible debenture financing. 6,250,000 Warrants will have an exercise price of $0.17 per Common Share (the "$0.17 Warrants").

  • GlobeNewswire

    Emerald Health Therapeutics Releases First Harvest of Premium Cannabis from its 100%-Owned Cultivation Facility in Richmond, BC

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced that the first shipment of its own unique version of the cannabis strain, Chemdog, from its 100%-owned Richmond facility is now available through the BC Liquor Distribution Board’s online site and will become available in certain licensed cannabis retail stores in British Columbia. Emerald’s version of Chemdog, a sativa-dominant hybrid strain with 19-25% THC and 0-1% CBD, is the first of five unique strains that Emerald is growing and harvesting in its new Richmond, BC, operation.

  • Baystreet

    Stocks in play: Emerald Health Therapeutics, Inc.

    Announced that its Pure Sunfarms joint venture has finalized the expansion of its credit facility with ...

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms JV Expands Credit Facility with Existing Lender by up to $59M and Completes Additional $8M Financing

    VANCOUVER, British Columbia, April 03, 2020 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its Pure Sunfarms (“PSF”) joint venture.

  • ACCESSWIRE

    Emerald Health Therapeutics' Pure Sunfarms JV Expands Credit Facility with Existing Lender by up to $59M

    VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) announced that its Pure Sunfarms ("PSF") joint venture has expanded ...

  • ACCESSWIRE

    Emerald Health Therapeutics’ Joint Venture, Pure Sunfarms, Reports Positive Operating and Financial Growth in 2019, with Significant EBITDA Performance of $54.1 Million

    VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has provided audited financial results for the fourth quarter and year of 2019 for its British Columbia-based joint venture, Pure Sunfarms (PSF). Net sales, consisting entirely of dried cannabis, for the year and fourth quarter of 2019 were $82.8 million and $12.1 million, respectively, compared to $4.9 million and $4.7 million. "All-in" cost of cultivation (including depreciation) for the year was $0.78 per gram and for the fourth quarter was $0.66 per gram.

  • ACCESSWIRE

    Emerald Health Therapeutics’ Pure Sunfarms JV Receives Health Canada Approval for State-of-the-Art Processing Centre

    VANCOUVER, BC / ACCESSWIRE / March 23, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (EMH.V)(EMHTF) announced that its Pure Sunfarms (PSF) joint venture has received approval from Health Canada for the final components of its 65,000 square foot state-of-the-art processing center. This additional processing space enables PSF to further optimize processing operations and throughput, realize additional production cost efficiencies, expand product offerings, and further elevate the quality of its products. "The approval of this additional processing space enables Pure Sunfarms to enhance our operations and quality processes to further support our commitment to providing our customers with high-quality products at a great price," said Mandesh Dosanjh, President and CEO, Pure Sunfarms.

  • GlobeNewswire

    Emerald Health Therapeutics Signs LOI with Sigma Analytical Services

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) (“Emerald”) has signed a letter of intent under which Sigma Analytical Services Inc. (“Sigma”), a full-service GMP-compliant testing laboratory for cannabis, hemp, and derived products, may acquire Emerald’s Avalite cannabis analytical testing operation. Execution of definitive agreements is subject to due diligence and board approval of both companies and is expected to occur on or before April 19, 2020.

  • GlobeNewswire

    Emerald Health Therapeutics, Pure Sunfarms, and Village Farms Complete Settlement of All Disputes

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release dated March 3, 2020, all transactions contemplated by the settlement agreement (the "Settlement Agreement") among Emerald, Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF" and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties have been completed. As such, the arbitration process involving the Parties has been discontinued.

  • GlobeNewswire

    Emerald Health Therapeutics, Pure Sunfarms, and Village Farms Settle All Disputes

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has entered into a settlement agreement (the "Settlement Agreement") with Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF," and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties (the "Settlement"). On completion of the Settlement the arbitration process involving the Parties will be discontinued.

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Makes First Cannabis Shipment to Alberta

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has completed its first shipment of cannabis under its supply agreement with Alberta Gaming, Liquor & Cannabis (AGLC). Pure Sunfarms’ recreational adult-use cannabis products will be available on Alberta’s only legal online store (AlbertaCannabis.org) in the first week of March and can be purchased by the province’s licensed private sector retailers. The AGLC is the wholesaler to private retailers and the only authorized online retailer in Alberta.

  • GlobeNewswire

    Emerald Health Therapeutics Closes Final Tranche Prospectus Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has closed the final tranche of its $3,000,000 prospectus offering (the “Offering”), announced in its news release dated January 6, 2020. Pursuant to this final closing, Emerald has issued an aggregate of 2,748,276 units of Emerald (each, a "Unit") at a price of $0.29 per Unit for total gross proceeds of $797,000. The initial tranche of the Offering closed on February 6, 2020 for gross proceeds of $2,203,000.

  • GlobeNewswire

    Emerald Health Therapeutics Closes $2.2 Million Prospectus Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has closed the first tranche of its $3,000,000 prospectus offering (the “Offering”) announced in its news release dated January 6, 2020. Pursuant to this initial closing, Emerald has issued an aggregate of 7,596,551 units of Emerald (each, a "Unit") at a price of $0.29 per unit for total gross proceeds of $2,203,000. Emerald will issue the remaining 2,748,276 Units, for gross proceeds of $797,000, upon receipt of all necessary approvals, including the approval of the TSX Venture Exchange and applicable securities regulatory authorities.

  • Should You Be Concerned About Emerald Health Therapeutics, Inc.'s (CVE:EMH) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Emerald Health Therapeutics, Inc.'s (CVE:EMH) Historical Volatility?

    If you own shares in Emerald Health Therapeutics, Inc. (CVE:EMH) then it's worth thinking about how it contributes to...

  • GlobeNewswire

    Emerald Health Therapeutics Closes Shares for Debt Financing

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), is pleased to announce that it has closed its previously announced shares for debt financing. Further to its news release dated January 27, 2020, Emerald has settled $2,816,963 (the "Debt") of the aggregate debt owed by Emerald to Emerald Health Sciences Inc. ("Sciences"), a control person of Emerald, in exchange for the issuance of 9,713,666 common shares of Emerald (each, a "Debt Share") at a deemed value of $0.29 per Debt Share (the "Debt Settlement"). The Debt consists of: (i) $794,182 owed to Sciences pursuant to a previously disclosed loan agreement between the parties; and (ii) $2,022,781 owed to Sciences pursuant to trades payable.

  • GlobeNewswire

    Emerald Health Therapeutics Provides Update on Financing Transactions

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today provided an update on a previously announced shares for debt transaction. Further to its news release dated December 16, 2019, Emerald will be settling $2,816,963 (the "Debt") of the aggregate debt owed by Emerald to Emerald Health Sciences Inc. ("Sciences"), a control person of Emerald. Emerald will satisfy the Debt by issuing 9,713,666 common shares of Emerald (each, a "Debt Share") at a deemed value of $0.29 per Debt Share (the "Debt Settlement").

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Partner Withdraws Purported $5.94 Million Investment in Pure Sunfarms

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that Village Farms International, Inc. ("Village Farms") has withdrawn its attempt to make an unsupported  additional equity contribution in their joint venture, Pure Sun Farms Corp. (“PSF”). Village Farms has rescinded the attempt and has requested and received a refund of the $5.94 million it advanced to PSF in November 2019. The previously announced arbitration proceedings between the parties remain in process with respect to Emerald’s right to set-off a $5.94 million payment owed by Emerald to PSF against a portion of the more than $13 million currently owed by PSF to Emerald under its shareholder loan.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Second Tranche of $4.5 Million Financing

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with certain institutional accredited investors (the “Investors”) under which the Investors have agreed, subject to certain customary conditions, to purchase 10,344,827 units of Emerald (each, a "Unit") at a price of $0.29 per Unit for total gross proceeds of $3,000,000 (the "Offering").

  • GlobeNewswire

    Emerald Health Therapeutics Closes Initial Tranche of Private Placement

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), announced today that it has closed the initial tranche of a private placement which was announced on December 16, 2019. Emerald has closed the initial tranche (the "Initial Tranche") of its previously announced non-brokered private placement (the "Private Placement") for gross proceeds of $1,500,153.

  • GlobeNewswire

    Emerald Health Therapeutics Enters into Multi-Year Extraction and White Label Service Agreement with Valens

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has entered into a multi-year agreement (the "Agreement") with Valens GroWorks Corp. (“Valens” or “The Valens Company”) (TSXV: VLNS; OTCQX: VLNCF) to contract cannabis extraction and white-label product development services. Under the Agreement, which has a 4-year term, Emerald will supply Valens with a minimum of 10,000 kg of cannabis and hemp biomass annually for processing on a fee for service basis into premium quality resins and distillates using Valens’ leading proprietary extraction and processing methods.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Financing Transactions

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced today that it is carrying out a financing and entering into a shares for debt transaction. Emerald intends to complete a non-brokered private placement (the "Private Placement"), in one or more tranches, of a minimum of 5,172,414 units of Emerald (each, a "Unit") and a maximum of 15,517,241 Units at a price of $0.29 per Unit, for gross proceeds of a minimum of $1,500,000 and a maximum of $4,500,000. Each Unit will consist of one common share of Emerald (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics Reports Third Quarter 2019 Financial Results; Sales Double Third Quarter in a Row

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and nine-month period ended September 30, 2019. Full versions of the Company’s unaudited condensed, interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com. Net loss of $17.5M impacted by $2.8M inventory write down and decrease of $9.1M in fair value adjustments of biological assets.

  • GlobeNewswire

    Emerald Health Therapeutics Closes $2.5 Million Prospectus Sale and Concurrent Secondary Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), announced today that it closed its prospectus sale (the "Offering") to a single Canadian institutional accredited investor (the “Investor”), as announced on November 13, 2019. Each Unit consists of one common share of Emerald (each, a "Common Share") and one common share purchase warrant (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics Maintains 50% Share Ownership in Pure Sunfarms

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today responded to misleading public disclosure made by Village Farms International, Inc. ("Village Farms") (TSX: VFF; Nasdaq: VFF) yesterday in connection with their joint venture, Pure Sunfarms Corp. ("PSF"). Emerald reiterates the disclosure in its November 20, 2019, news release and confirms that, factually, Emerald and Village Farms each continue to own 50% of PSF. As set out in Village Farms’ own news release, no additional shares of PSF have been issued to Village Farms and none of Emerald’s escrowed shares in PSF have been cancelled.